|Over a week ago|
Stifel cuts estimates, targets for five MedTech stocks following doctor survey » 08:1203/2403/24/20
BSX, ISRG, LIVN, SYK, ZBH
Stifel analyst Rick Wise…
Stifel analyst Rick Wise said his recent survey of 114 physicians made it "abundantly clear that COVID-19 disruptions for non-emergent/elective procedures could face significant reductions" and he has accordingly lowered his sales and EPS estimates for MedTech companies Boston Scientific (BSX), Intuitive Surgical (ISRG), LivaNova (LIVN), Stryker (SYK) and Zimmer Biomet (ZBH). He lowered his price target for Boston Scientific shares to $30 from $47, cut his target for Intuitive share to $425 from $665, halved his target for LivaNova to $40 from $80, reduced his target for Stryker to $145 from $250 and decreased his Zimmer target to $93 from $180, but keeps Buy ratings on all five stocks citing his "firm belief and hope that the current COVID-19 situation will ease in coming months."
LivaNova receives CE Mark approval for Symmetry to treat DTD » 09:0803/0903/09/20
LivaNova announced its…
LivaNova announced its Vagus nerve stimulation therapy, or VNS Therapy System, Symmetry, earned CE Mark approval for difficult-to-treat depression, or DTD. Two patients in the United Kingdom were implanted at the Musgrove Park Hospital in Taunton, England, making them the first patients to receive Symmetry devices outside the United States. The ability to treat these patients with Symmetry was the result of a collaborative effort to develop a VNS Therapy for depression treatment pathway by the Somerset Partnership National Health Service Foundation Trust, the Taunton and Somerset NHS Foundation Trust and LivaNova.
|Over a month ago|
LivaNova jumps after Reorg says Medtronic buyout talks in early stage » 14:2902/2702/27/20
Shares of LivaNova (LIVN)…
Shares of LivaNova (LIVN) rallied after Reorg, according to Bloomberg, reported that Medtronic is in early stage buyout talks with the company. Medtronic was pitched recently on acquiring LivaNova and the proposal has gained traction, Reorg said, Bloomberg reported. Shares of LivaNova are up 8%, or $5.02, to $67.72 following the report.
LivaNova buyout gained traction at Medtronic, talks early, Reorg says 14:2502/2702/27/20
Reported by Bloomberg.
Medtronic pitched LivaNova buyout recently, Reorg says, Bloomberg reports 14:2402/2702/27/20
LivaNova enters research collaboration with Alphabet's Verily » 16:4602/2602/26/20
LIVN, GOOG, GOOGL
LivaNova PLC (LIVN)…
LivaNova PLC (LIVN) announced a research collaboration with Verily, an Alphabet (GOOGL) company, to capture measures of depression within its RECOVER clinical study, which is evaluating the effectiveness of Vagus Nerve Stimulation Therapy for Difficult-to-Treat Depression. Through this initial research collaboration, LivaNova and Verily aim to gather quantitative data on patient behavior using technology and analytics developed by Verily to further understand depressive episodes and a patient's response to treatment. RECOVER clinical sites will have the ability to offer patients the Verily Study Watch, a wearable device designed to capture physiological and environmental data for clinical research, and a Verily mobile phone app. These complementary approaches are expected to help investigators better understand the impact of depression and its treatment on study participants' lives in a more objective and multi-dimensional manner.
Piper Sandler backs Overweight rating on LivaNova despite 'noisy' quarter » 13:4602/2602/26/20
Piper Sandler analyst…
Piper Sandler analyst Matt O'Brien said LivaNova reported a "noisy" fourth quarter along with initial FY20 guidance that was "a bit light" compared to consensus. He believes the guidance miss is mainly due to management's conservatism and notes his view that key new product launches in HLM, ACS, and Neuromod over the next year or so should buoy results. O'Brien, who predicts the company's depression drug that is under development "will be a massive value creator in the coming years, maintains an Overweight rating on LivaNova, but lowered his price target on the shares to $80 from $90.
LivaNova sees FY20 adjusted EPS $3.10-$3.30, consensus $3.30 » 06:0402/2602/26/20
Expects FY20 revenues to…
Expects FY20 revenues to grow 3%-5% on a constant-currency basis, consensus $1.15B. In 2020, the company estimates that adjusted cash flow from operations, excluding litigation payments, will be in the range of $180M-$200M. Capital expenditures are projected at $25M-$35M.
LivaNova reports Q4 adjusted EPS $1.00, consensus 98c » 06:0202/2602/26/20
Reports Q4 revenue…
Reports Q4 revenue $287.6M, consensus $295.49M.
LivaNova reports FDA clearance for 3T Heater-Cooler device modification » 14:0302/2502/25/20
LivaNova announced it…
LivaNova announced it received U.S. Food and Drug Administration 510(k) clearance for a device modification to its 3T Heater-Cooler devices. "The modification includes the installation of a 3T Aerosol Collection Set, as well as testing that demonstrates the effectiveness of its operating instructions. This modification has been implemented at no cost to customers on devices that have already been distributed and is being implemented on new units being prepared for distribution. Collectively, these modifications further reduce the potential risk of possible dispersion of aerosols in hospital operating rooms when used in accordance with Operating Instructions. Devices manufactured in accordance with this newly cleared 510(k) will not be subject to the current FDA import alert," the company said. Bryan Olin, LivaNova Senior Vice President for Clinical, Quality and Regulatory Affairs, added: "FDA clearance allows us to implement a permanent design solution for 3T Heater-Cooler devices used in the U.S. that further mitigates the potential risk of aerosolization. Heater-coolers are critical pieces of equipment for open-heart surgery, and LivaNova wants to ensure continued access to these important devices for the ongoing treatment of patients around the world."